vs
Side-by-side financial comparison of PHOTRONICS INC (PLAB) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
PHOTRONICS INC is the larger business by last-quarter revenue ($210.4M vs $129.7M, roughly 1.6× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -5.5%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -3.8%).
Photronics, Inc. is an American semiconductor photomask manufacturer. It was the third largest photomask supplier globally as of 2009. Photronics is a member of the eBeam Initiative.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
PLAB vs TVTX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $210.4M | $129.7M |
| Net Profit | $22.9M | — |
| Gross Margin | 33.7% | 98.0% |
| Operating Margin | 22.9% | -25.0% |
| Net Margin | 10.9% | — |
| Revenue YoY | -5.5% | 73.4% |
| Net Profit YoY | -32.4% | — |
| EPS (diluted) | $0.39 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $129.7M | ||
| Q3 25 | $210.4M | $164.9M | ||
| Q2 25 | $211.0M | $114.4M | ||
| Q1 25 | $212.1M | $81.7M | ||
| Q4 24 | $222.6M | $74.8M | ||
| Q3 24 | $211.0M | $62.9M | ||
| Q2 24 | $217.0M | $54.1M | ||
| Q1 24 | $216.3M | $41.4M |
| Q4 25 | — | — | ||
| Q3 25 | $22.9M | $25.7M | ||
| Q2 25 | $8.9M | $-12.8M | ||
| Q1 25 | $42.9M | $-41.2M | ||
| Q4 24 | $33.9M | — | ||
| Q3 24 | $34.4M | $-54.8M | ||
| Q2 24 | $36.3M | $-70.4M | ||
| Q1 24 | $26.2M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | 33.7% | 99.0% | ||
| Q2 25 | 36.9% | 98.7% | ||
| Q1 25 | 35.6% | 94.3% | ||
| Q4 24 | 37.0% | 96.6% | ||
| Q3 24 | 35.6% | 97.4% | ||
| Q2 24 | 36.5% | 96.2% | ||
| Q1 24 | 36.6% | 96.4% |
| Q4 25 | — | -25.0% | ||
| Q3 25 | 22.9% | 15.1% | ||
| Q2 25 | 26.4% | -11.1% | ||
| Q1 25 | 24.6% | -52.2% | ||
| Q4 24 | 25.1% | -81.2% | ||
| Q3 24 | 24.7% | -89.3% | ||
| Q2 24 | 25.8% | -125.1% | ||
| Q1 24 | 26.6% | -336.5% |
| Q4 25 | — | — | ||
| Q3 25 | 10.9% | 15.6% | ||
| Q2 25 | 4.2% | -11.1% | ||
| Q1 25 | 20.2% | -50.4% | ||
| Q4 24 | 15.2% | — | ||
| Q3 24 | 16.3% | -87.1% | ||
| Q2 24 | 16.7% | -130.1% | ||
| Q1 24 | 12.1% | -328.9% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | $0.39 | $0.28 | ||
| Q2 25 | $0.15 | $-0.14 | ||
| Q1 25 | $0.68 | $-0.47 | ||
| Q4 24 | $0.54 | $-0.71 | ||
| Q3 24 | $0.55 | $-0.70 | ||
| Q2 24 | $0.58 | $-0.91 | ||
| Q1 24 | $0.42 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $575.8M | $93.0M |
| Total DebtLower is stronger | $16.0K | — |
| Stockholders' EquityBook value | $1.1B | $114.8M |
| Total Assets | $1.8B | $605.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | $575.8M | $110.9M | ||
| Q2 25 | $558.4M | $75.2M | ||
| Q1 25 | $642.2M | $61.9M | ||
| Q4 24 | $640.7M | $58.5M | ||
| Q3 24 | $606.4M | $36.4M | ||
| Q2 24 | $559.9M | $32.3M | ||
| Q1 24 | $521.5M | $43.3M |
| Q4 25 | — | — | ||
| Q3 25 | $16.0K | — | ||
| Q2 25 | $19.0K | — | ||
| Q1 25 | $21.0K | — | ||
| Q4 24 | $25.0K | — | ||
| Q3 24 | $28.0K | — | ||
| Q2 24 | $2.5M | — | ||
| Q1 24 | $2.7M | — |
| Q4 25 | — | $114.8M | ||
| Q3 25 | $1.1B | $73.6M | ||
| Q2 25 | $1.1B | $32.7M | ||
| Q1 25 | $1.1B | $32.8M | ||
| Q4 24 | $1.1B | $59.1M | ||
| Q3 24 | $1.1B | $-30.5M | ||
| Q2 24 | $1.0B | $15.1M | ||
| Q1 24 | $1.0B | $74.1M |
| Q4 25 | — | $605.2M | ||
| Q3 25 | $1.8B | $538.6M | ||
| Q2 25 | $1.7B | $555.3M | ||
| Q1 25 | $1.7B | $548.8M | ||
| Q4 24 | $1.7B | $594.1M | ||
| Q3 24 | $1.6B | $504.4M | ||
| Q2 24 | $1.6B | $551.1M | ||
| Q1 24 | $1.6B | $663.5M |
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $50.1M | $60.7M |
| Free Cash FlowOCF − Capex | $25.2M | — |
| FCF MarginFCF / Revenue | 12.0% | — |
| Capex IntensityCapex / Revenue | 11.8% | — |
| Cash ConversionOCF / Net Profit | 2.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $64.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $60.7M | ||
| Q3 25 | $50.1M | $14.3M | ||
| Q2 25 | $31.5M | $5.0M | ||
| Q1 25 | $78.5M | $-42.2M | ||
| Q4 24 | $68.4M | $-35.7M | ||
| Q3 24 | $75.1M | $-42.5M | ||
| Q2 24 | $76.5M | $-40.2M | ||
| Q1 24 | $41.5M | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | $25.2M | $14.2M | ||
| Q2 25 | $-29.1M | — | ||
| Q1 25 | $43.3M | — | ||
| Q4 24 | $25.2M | — | ||
| Q3 24 | $50.7M | — | ||
| Q2 24 | $56.5M | $-40.3M | ||
| Q1 24 | $-1.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | 12.0% | 8.6% | ||
| Q2 25 | -13.8% | — | ||
| Q1 25 | 20.4% | — | ||
| Q4 24 | 11.3% | — | ||
| Q3 24 | 24.0% | — | ||
| Q2 24 | 26.0% | -74.5% | ||
| Q1 24 | -0.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 11.8% | 0.1% | ||
| Q2 25 | 28.7% | — | ||
| Q1 25 | 16.6% | — | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 11.6% | 0.0% | ||
| Q2 24 | 9.2% | 0.2% | ||
| Q1 24 | 20.0% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 2.19× | 0.56× | ||
| Q2 25 | 3.55× | — | ||
| Q1 25 | 1.83× | — | ||
| Q4 24 | 2.02× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.11× | — | ||
| Q1 24 | 1.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLAB
| High End Integrated Circuits | $53.6M | 25% |
| High End Flat Panel Displays | $53.5M | 25% |
| KR | $43.7M | 21% |
| Other | $42.1M | 20% |
| Mainstream Flat Panel Displays | $9.1M | 4% |
| Transferred At Point In Time | $8.4M | 4% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
